The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Another site added previously 94, today 95
https://clinicaltrials.gov/ct2/show/NCT04518410?term=ACTIV-2&draw=2
Seems as if Oxford are involved with the SNG001 hospital ph3 trial, just came across this on Twitter.
https://twitter.com/naj_rahman/status/1350828540309204993?s=21
Was Oxford one of the locations already identified on the trial??
Bought final lot (1276@154.7) on IG at 13:41hrs.....but i'm still waiting for order to be filled. Seems as if they are happy to accept on IG but may be a different matter if the order gets filled or not??
Polar have 3.2% of their portfolio in SNG, which equates to 10% of SNG shares
https://www.polarcapital.co.uk/gb/professional/Our-Funds/Biotechnology#/Portfolio
https://www.synairgen.com/investors/major-shareholders/
It needs to do something, how are we lower than yesterday close with the news we've read over the previous 24hrs.......just struggling to see sense?
My patience may 'imminently'resume.......possibly 4 weeks down the line
To follow on from kevkan. If we have 100,000 treatments per month and with the phase III running in c.20 countries, what happens when EUA is granted? Are the 100k treatments solely for the uk arm or is the supply for the entirety? Licensing surely has to follow suit to enable each country to benefit and roll out?
To be involved in a trial and see improved recovery/hospital discharge time, there must be some form of agreement for all to benefit when results are in
Matterhorn, you have linked it to OWS. I originally read it as respectively with the two drugs being one in OWS and our SNG being in NIHR trial.
With your provided link that confirms they are both in OWS, great work!!
E.8.4.1 states Number of sites anticipated in Member State concerned 20
F.4.1 states member state 200
10 per participants per NHS site, I wonder why 26 countries and not the 20 as originally stated?
Apologies if already posted, had a day away from the screen and too many message to backtrack.
New antivirals are also being developed for mild outpatient cases, including MK-4482 from Merck and Synairgen’s SNG001. These have been facilitated by Operation Warp Speed and the NIH’s ACTIV-2 (Adaptive Platforms Treatment Trial for Outpatients with COVID-19) trials.7 Although we are in the first stages of these clinical trials, the preliminary data seems promising.
https://www.hsgac.senate.gov/imo/media/doc/Testimony-Jha-2020-11-19.pdf